𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia

✍ Scribed by Tadeusz Robak; Piotr Smolewski; Barbara Cebula; Olga Grzybowska-Izydorczyk; Jerzy Z. Błoński

Book ID
114794220
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
543 KB
Volume
79
Category
Article
ISSN
0902-4441

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Low-dose oral fludarabine plus cyclophos
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia
✍ Francesco Forconi; Alberto Fabbri; Mariapia Lenoci; Elisa Sozzi; Alessandro Gozz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB

## Abstract Fludarabine plus cyclophosphamide (FC) at conventional doses is an effective treatment for chronic lymphocytic leukaemia (CLL). However, FC at standard doses may give hematological and non‐hematological toxicity, predominantly in the elderly. Intravenous or oral low‐dose FC regimens rem

Pentostatin, cyclophosphamide, and ritux
Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia
✍ Tait D. Shanafelt; Thomas Lin; Susan M. Geyer; Clive S. Zent; Nelson Leung; Bria 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 1 views

## Abstract ## BACKGROUND. The prevalence of chronic lymphocytic leukemia (CLL) increases with age. Although chemoimmunotherapy (CIT) has dramatically improved response rates in patients with CLL, some CIT regimens are not well tolerated by many patients ≥70 years of age. ## METHODS. Sixty‐four